I agree that this site is using cookies. You can find further informations here.
X
de Botton, Stephane
282  results:
Search for persons X
?
1

Final phase I substudy results of ivosidenib in patients wi..:

DiNardo, Courtney D. D ; Roboz, Gail J. ; Watts, Justin M...
Blood Advances.  , 2024
Link: https://doi.org/10.1182/..
 
?
2

Somatic gene mutation patterns and burden influence outcome..:

Risueño, Alberto ; See, Wendy L. ; Bluemmert, Iryna...
Leukemia Research.  140 (2024)  - p. 107497 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Differentiation syndrome associated with treatment with IDH..:

Montesinos, Pau ; Fathi, Amir T. ; de Botton, Stéphane...
Blood Advances.  8 (2024)  10 - p. 2509-2519 , 2024
Link: https://doi.org/10.1182/..
 
?
4

When monoclonal gammopathy‐associated chronic neutrophilic ..:

Willekens, Christophe ; Chahine, Claude ; Dragani, Matteo...
eJHaem.  4 (2023)  3 - p. 823-826 , 2023
Link: https://doi.org/10.1002/..
 
?
5

MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refractory Myelo..:

DiNardo, Courtney D. ; Roboz, Gail J. ; Watts, Justin M....
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S366-S367 , 2023
Link: https://doi.org/10.1016/..
 
?
6

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTAN..:

Dinardo, Courtney ; Roboz, Gail ; M. Watts, Justin...
HemaSphere.  7 (2023)  S3 - p. e75740ab , 2023
Link: https://doi.org/10.1097/..
 
?
7

PB1884: ENGAGING INNATE IMMUNITY: A PHASE 1 DOSE ESCALATION..:

Arnan, Montserrat ; Montesinos, Pau ; Botton, Stéphane de...
HemaSphere.  7 (2023)  S3 - p. e2404792 , 2023
Link: https://doi.org/10.1097/..
 
?
8

P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR44..:

Selwyn Stein, Anthony ; Jongen-Lavrencic, Mojca ; Garciaz, Sylvain...
HemaSphere.  7 (2023)  S3 - p. e66387cd , 2023
Link: https://doi.org/10.1097/..
 
?
9

P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RES..:

Döhner, Hartmut ; Montesinos, Pau ; Vives Polo, Susana...
HemaSphere.  7 (2023)  S3 - p. e83152da , 2023
Link: https://doi.org/10.1097/..
 
?
10

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND..:

Botton, Stéphane de ; Cluzeau, Thomas ; Vigil, Carlos...
HemaSphere.  7 (2023)  S3 - p. e50253dc , 2023
Link: https://doi.org/10.1097/..
 
?
11

POSTER: AML-469 Ivosidenib + Azacitidine vs Placebo + Azaci..:

de Botton, Stéphane ; Montesinos, Pau ; Polo, Susana Vives...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S166 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Safety, efficacy, and PK/PD of vorasidenib in previously tr..:

DiNardo, Courtney D. ; De Botton, Stéphane ; Pollyea, Daniel A....
American Journal of Hematology.  98 (2023)  9 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
13

Use of tamibarotene, a potent and selective RARα agonist, i..:

Stein, Eytan M. ; de Botton, Stephane ; Cluzeau, Thomas...
Leukemia & Lymphoma.  64 (2023)  12 - p. 1992-2001 , 2023
Link: https://doi.org/10.1080/..
 
?
14

Enasidenib treatment in two individuals with D-2-hydroxyglu..:

Geoerger, Birgit ; Schiff, Manuel ; Penard-Lacronique, Virginie...
Nature Medicine.  29 (2023)  6 - p. 1358-1363 , 2023
Link: https://doi.org/10.1038/..
 
?
15

Enasidenib vs conventional care in older patients with late..:

de Botton, Stéphane ; Montesinos, Pau ; Schuh, Andre C....
Blood.  141 (2023)  2 - p. 156-167 , 2023
Link: https://doi.org/10.1182/..
 
1-15